Dexrazoxane - Satiscor

Drug Profile

Dexrazoxane - Satiscor

Alternative Names: Dexrazoxane hydrochloride - Satiscor

Latest Information Update: 26 Aug 2016

$50 / €47 *
* $ price applies to USA, Canada and Latin America. € price applies to the rest of the world. Final gross prices may vary according to local VAT.

At a glance

  • Originator Satiscor
  • Class Adjunct therapies; Chemoprotectants; Piperazines; Small molecules
  • Mechanism of Action Iron chelating agents; Type II DNA topoisomerase inhibitors
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    Yes - Cardiomyopathies
  • New Molecular Entity No

Highest Development Phases

  • Preclinical Cardiomyopathies

Most Recent Events

  • 26 Aug 2016 Chemical structure information added
  • 04 Aug 2016 Preclinical trials in Cardiomyopathy (Prevention, In infants, In children, In adolescents) in USA (unspecified route)
  • 19 Aug 2014 Dexrazoxane hydrochloride - Satiscor receives Orphan Drug status for Cardiomyopathy (Prevention, In infants, In children, In adolescents) in USA
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top